GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Intrinsic Value: Projected FCF

AbbVie (AbbVie) Intrinsic Value: Projected FCF : $118.96 (As of Apr. 27, 2024)


View and export this data going back to 2012. Start your Free Trial

What is AbbVie Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-27), AbbVie's Intrinsic Value: Projected FCF is $118.96. The stock price of AbbVie is $159.62. Therefore, AbbVie's Price-to-Intrinsic-Value-Projected-FCF of today is 1.3.

The historical rank and industry rank for AbbVie's Intrinsic Value: Projected FCF or its related term are showing as below:

ABBV' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.29   Med: 1.35   Max: 2.15
Current: 1.34

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of AbbVie was 2.15. The lowest was 1.29. And the median was 1.35.

ABBV's Price-to-Projected-FCF is ranked better than
56.35% of 598 companies
in the Drug Manufacturers industry
Industry Median: 1.525 vs ABBV: 1.34

AbbVie Intrinsic Value: Projected FCF Historical Data

The historical data trend for AbbVie's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Intrinsic Value: Projected FCF Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.99 81.10 104.61 122.74 118.96

AbbVie Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.74 119.53 120.30 122.61 118.96

Competitive Comparison of AbbVie's Intrinsic Value: Projected FCF

For the Drug Manufacturers - General subindustry, AbbVie's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where AbbVie's Price-to-Projected-FCF falls into.



AbbVie Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get AbbVie's Free Cash Flow(6 year avg) = $18,088.48.

AbbVie's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(11.222205783355*18088.48+10360*0.8)/1776.000
=118.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbbVie  (NYSE:ABBV) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

AbbVie's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=159.62/118.96432706537
=1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbbVie Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of AbbVie's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie (AbbVie) Business Description

Industry
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Executives
Nicholas Donoghoe officer: SVP, Enterprise Innovation 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin director 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis director 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalez officer: Chairman of the Board and CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg officer: Sr. V.P., U.S. Commercial Ops. 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis officer: EVP, GC and Secretary 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart officer: SVP, US Commercial Operations 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee officer: SVP, Controller 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents officer: SVP, Chief Financial Officer 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt officer: SVP, Operations 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom officer: SVP & Pres Global Allerg Aesth 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin director 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmond officer: EVP, Chief HR Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severino officer: EVP, R&D and CSO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruch officer: Chief Strategy Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092

AbbVie (AbbVie) Headlines

From GuruFocus

Q3 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc will Acquire ImmunoGen Inc M&A Call Transcript

By GuruFocus Research 01-22-2024